Treatment of vitiligo: Current methods and new approaches

Acta Dermatovenerologica Croatica

Volumn 11, Issue 3, 2003, Pages 163-170

  Kostović, Krešimir ^a   Nola, Ivana ^a   Bučvan, Željana ^a   Šitum, Mirna ^a  

^a SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

Author keywords

Immunosuppressive agents; Lasers; Photochemotherapy; Phototherapy; Vitiligo

Indexed keywords

CORTICOSTEROID; HYDROQUINONE; LEVAMISOLE; MONOBENZONE; TACROLIMUS; VITAMIN D DERIVATIVE;

CLINICAL TRIAL; CONTACT DERMATITIS; DEPIGMENTATION; EXCIMER LASER; HUMAN; MELANOCYTE; PUVA; RADIOTHERAPY; REVIEW; SIDE EFFECT; SKIN GRAFT; ULTRAVIOLET B RADIATION; VITILIGO;

HUMANS; THERAPEUTICS; TIME FACTORS; VITILIGO;

EID: 0141670326     PISSN: 1330027X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Shaffrali F, Gawkrodger DJ. Management in vitiligo. Clin Exp Dermatol 2000;25:575-9.
2. Taneja A. Treatment of vitiligo. J Dermatolog Treat 2002;13:19-25.
3. Naughton GK, Eisinger M, Bystryn JC. Antibodies to normal melanocytes in vitiligo. J Exp Med 1983;158:246-51.
4. Kemp EH, Waterman EA, Gawkrodger DJ, Watson PF, Weetman AP. Identificaton of epitopes on tyrosinase which are recognised by autoantibodies from patients with vitiligo. J Invest Dermatol 1999;113:267-71.
5. Bystryn JC. Immune mechanisms in vitiligo. Clin Dermatol 1997;15:853-61.
6. Al' Abadie MS, Senior HJ, Bleehen SS, Gawkrodger DJ. Neuropeptide and neuronal marker studies in vitiligo. Br J Dermatol 1994;131:160-5.
7. Lerner AB. Vitiligo. J Invest Dermatol 1959;32:285-310.
8. Lerner AB. On the aetiology of vitiligo and gray hair. Am J Med 1971;51:141-7.
9. Schallreuter KU, Wood JM, Ziegler I, Lemke KR, Pittelkow MR, Lindsey NJ, et al. Defective tetrahydrobiopterin and catecholamine biosynthesis in the depigmentation disorder vitiligo. Biochim Biophys Acta. 1994;1226:181-92.
10. Kovacs SO. Vitiligo. J Am Acad Dermatol 1998;38 :647-66.
11. McNeely W, Goa KL. 5-methoxypsoralen. A review of its effects in psoriasis and vitiligo. Drugs 1998;56: 667-90.
12. Halder RM, Young CM. New and emerging therapies for vitiligo. Dermatol Clin 2000;18:79-89.
13. Wildfang IL, Jacobsen FK, Thestrup-Pedersen K. PUVA treatment of vitiligo: a retrospective study of 59 patients. Acta Derm Venereol 1992;72:305-6.
14. Grimes PE. Psoralen photochemotherapy for vitiligo. Clin Dermatol 1997;15:921-6.
15. Kwok YK, Anstey AV, Hawk JL. Psoralen photochemotherapy (PUVA) is only moderately effective in widespread vitiligo: a 10-year retrospective study. Clin Exp Dermatol 2002;27:104-10.
16. Ortonne J. Psoralen therapy in vitiligo. Clin Dermatol 1989;7:120-35.
17. Parrish J, Fitzpatrick T, Shea C, Pathak MA. Photochemotherapy of vitiligo. Use of orally administered psoralens and a high-intensity long-wave ultraviolet light system. Arch Dermatol 1976;112:1531-4.
18. British Photodermatology Group. British photodermatology group guidelines for PUVA. Br J Dermatol 1994;130:246-55.
19. Arrunategui A, Arroyo C, Garcia L, Covelli C, Escobar C, Carrascal E, et al. Melanocyte reservoir in vitiligo. Int J Dermatol 1994;33:484-7.
20. Norris DA, Horikawa T, Morelli JG. Melanocyte destruction and repopulation in vitiligo. Pigment Cell Res 1994;7:193-203.
21. Imokawa G, Yada Y, Miyagishi M. Endothelins secreted from human keratinocytes are intrinsic mitogens for human melanocytes. J Biol Chem 1992;267:24675-80.
22. Yohn J, Morelli J, Walchak S, Rundell KB, Norris DA, Zamora MR, et al. Cultured human keratinocytes synthesize and secrete endothelin-1. J Invest Dermatol 1993;100:23-6.
23. Halaban R, Langdon R, Birchall N, Cuono C, Baird A, Scott G, et al. Basic fibroblast growth factor from human keratinocytes is a natural mitogen for melanocytes. J Cell Biol 1988;107:1611-9.
24. Gordon P, Mansur C, Gilchrest B. Regulation of human melanocyte growth, dendricity, and melanization by keratinocyte derived factors. J Invest Dermatol 1989;92:565-72.
25. Morelli JG, Yohn JJ, Lyons MB, Murphy RC, Norris DA. Leukotrienes C4 and D4 as potent mitogens for cultured human neonatal melanocytes. J Invest Dermatol 1989;93:719-22.
26. Njoo MD, Westerhof W. Vitiligo. Pathogenesis and treatment. Am J Clin Dermatol 2001;2:167-81.
27. British Photodermatology Group. An appraisal of narrow-band (TL-01) UV-B phototherapy. British Photodermatology Group Workshop Report (April 1996). Br J Dermatol 1997;137:327-30.
28. Westerhof W, Nieuweboer-Krobotova L. Treatment of vitiligo with UV-B radiation vs topical psoralen plus UV-A. Arch Dermatol 1997;133:1525-8.
29. Scherschun L, Kim JJ, Lim HW. Narrow-band ultraviolet B is a useful and well-tolerated treatment for vitiligo. J Am Acad Dermatol 2001;44:999-1003.
30. Njoo MD, Bos JD, Westerhof W. Treatment of generalized vitiligo in children with narrow-band (TL-01) UVB radiation therapy. J Am Acad Dermatol 2000;42:245-53.
31. Baltas E, Csoma Z, Ignacz F, Dobozy A, Kemeny L. Treatment of vitiligo with the 308-nm xenon chloride excimer laser. Arch Dermatol 2002;138:1619-20.
32. Spencer JM, Nossa R, Ajmeri J. Treatment of vitiligo with the 308-nm excimer laser: a pilot study. J Am Acad Dermatol 2002;46:727-31.
33. Camacho F, Mazuecos J. Treatment of vitiligo with oral and topical phenylalanine: 6 years of experience. Arch Dermatol 1999;135:216-7.
34. Greiner D, Ochsendorf FR, Milbradt R. Vitiligo therapy with phenylalanine/ UV-A. Catamnestic studies after five years. Hautarzt 1994;45:460-3.
35. Rosenbach T, Wellenreuther U, Nurnberger F, Czarnetzki BM. Treatment of vitiligo with phenylalanine and UV-A. Hautarzt 1993;44:208-9.
36. Koga M. Vitiligo: a new classification and therapy. Br J Dermatol 1977;97:255-61.
37. Grimes P. Vitiligo. An overview of therapeutic approaches. Dermatol Clin 1993;11:325-38.
38. Kandil E. Vitiligo: response to 0.2% betamethasone 17-valerate in flexible collodion. Dermatologica 1970; 141:277-81.
39. Koopmans-van Dorp B, Goedhart-van Dijjk B, Neering H, van Dijk E. Treatment of vitiligo by local application of betamethsone 17-valerate in a dimethyl sulfoxide cream base. Dermatologica 1973;146:310-4.
40. Kandil E. Treatment of vitiligo with 0.1% betamethasone 17-valerate in isopropyl alcohol: a double-blind trial. Br J Dermatol 1974;91:457-60.
41. Kumari J. Vitiligo treated with topical clobetasol propionate. Arch Dermatol 1984;120:631-5.
42. Radakovic-Fijan S, Fürnsinn-Friedl AM, Hönigsmann H, Tanew A. Oral dexamethasone pulse treatment for vitiligo. J Am Acad Dermatol 2001;44:814-17.
43. Seiter S, Ugurel S, Tilgen W, Reingold U. Use of high-dose methylprednisolone pulse therapy in patients with progressive and stable vitiligo. Int J Dermatol 2000;39:624-7.
44. Liu XQ, Shao CG, Jin PY, Wang HQ, Ye GY, Yawalkar S. Treatment of localized vitiligo with Ulobetasol cream. Int J Dermatol 1990;29:295-7.
45. Hann SK, Kim HI, Im S, Park YK, Cui J, Bystryn JC. The change of melanocyte cytotoxicity after systemic steroid treatment in vitiligo patients. J Dermatol Sci 1993;6:201-5.
46. Hann SK, Chen D, Bystryn JC. Systemic steroids suppress antimelanocyte antibodies in vitiligo. J Cut Med Surg 1997;14:193-5.
47. Pasricha JS, Khera V. Effect of prolonged treatment with levamisole on vitiligo with limited and slow-spreading disease. Int J Dermatol 1994;33:584-7.
48. Grimes PE, Soriano T, Dytoc MT. Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol 2002;47:789-91.
49. Smith DA, Tofte SJ, Hanifin JM. Repigmentation of vitiligo with topical tacrolimus. Dermatology 2002; 205:301-3.
50. Yalcin B, Sahin S, Bukulmez G, Karaduman A, Atakan N, Akan T, et al. Experience with calcipotriol as adjunctive treatment for vitiligo in patients who do not respond to PUVA alone: a preliminary study. J Am Acad Dermatol 2001;44:634-7.
51. Ermis O, Alpsoy E, Cetin L, Yilmaz E. Is the efficacy of psoralen plus ultraviolet A therapy for vitiligo enhanced by concurrent topical calcipotriol? A placebo-controlled double-blind study. Br J Dermatol 2001;145:472-5.
52. Ameen M, Exarchou V, Chu AC. Topical calcipotriol as monotherapy and in combination with psoralen plus ultraviolet A in the treatment of vitiligo. Br J Dermatol 2001;145:476-9.
53. Chiaverini C, Passeron T, Ortonne JP. Treatment of vitiligo by topical calcipotriol. J Eur Acad Dermatol Venereol 2002;16:137-8.
54. Westerhof W, Nieuweboer-Krobotova L, Mulder PG, Glazenburg EJ. Left-right comparison study of the combination fluticasone propionate and UV-A vs either fluticasone propionate or UV-A alone for the long-term treatment of vitiligo. Arch Dermatol 1999; 135:1061-6.
55. Falabella R. What's new in the treatment of vitiligo? J Eur Acad Dermatol Venereol 2001;15:287-9.
56. Schallreuter KU, Moore J, Wood JM, Beazley WD, Peters EM, Marles LK, et al. Epidermal H2O2 accumulation alters tetrahydrobiopterin (6BH4) recycling in vitiligo: Identification of a general mechanism in regulation of all 6BH4-dependent processes? J Invest Dermatol 2001;116:167-74.
57. Schallreuter KU, Wood JM, Lemke KR, Levenig C. Treatment of vitiligo with a topical application of pseudocatalase and calcium in combination with shorter UVB exposure: a case study on 33 patients. Dermatology 1995;190:223-9.
58. Patel DC, Evans AV, Hawk JL. Topical pseudocatalase mousse and narrowband UVB phototherapy is not effective for vitiligo: an open, single-centre study. Clin Exp Dermatol 2002;27:614-4.
59. Morrone A, Picardo M, de Luca C, Terminali O, Passi S, Ippolito F. Catecholamines and vitiligo. Pigment Cell Res 1992;5:65-9.
60. Denton D, Lerner A, Fitzpatrick T. Inhibition of melanin formation by chemical agents. J Invest Dermatol 1951;18:119-35.
61. Passi S, Nazzaro-Porro M. Molecular basis of substrate and inhibitory specificity of tyrosinase: phenolic compounds. Br J Dermatol 1981;104:659-65.
62. Jimbow K, Obata H, Pathak MA, Fitzpatrick TB. Mechanism of depigmentation by hydroquinone. J Invest Dermatol 1974;62:436-49.
63. Nordlund JJ, Forget B, Kirkwood J, Lerner AB. Dermatitis produced by applications of monobenzone in patients with active vitiligo. Arch Dermatol 1985;121:1141-4.
64. Snider RI, Thiers BH. Exogenous ochronosis. J Am Acad Dermatol 1993;28:662-4.
65. Njoo MD, Vodegel RM, Westerhof W. Depigmentation therapy in vitiligo universalis with 4-methoxyphenol and Q-switched ruby laser. J Am Acad Dermatol 2000;42:760-9.
66. Thissen M, Westerhof W. Laser treatment for further depigmentation in vitiligo. Int J Dermatol 1997;36: 386-8.
67. Falabella R, Arrunategui A, Barona MI, Alzate A. The minigrafting test for vitiligo: detection of stable lesions for melanocyte transplantation. J Am Acad Dermatol 1995;32(2 Pt 1):228-32.
68. Westerhof W, Boersma B. The minigrafting test for vitiligo: detection of stable lesions for melanocyte transplantation. J Am Acad Dermatol 1995;33:1061-2.
69. Falabella R. Treatment of localized vitiligo by autologous minigrafting. Arch Dermatol 1988;124: 1649-55.
70. Falabella R. Repigmentation of segmental vitiligo by autologous minigrafting. J Am Acad Dermatol 1983;9:514-21.
71. Boersma B, Westerhof W, Boj J. Repigmentation in vitiligo vulgaris by autologous minigrafting: Results in nineteen patients. J Am Acad Dermatol 1995;33: 990-5.
72. Pai GS, Vinod V, Joshi A. Efficacy of erbium YAG laser-assisted autologous epidermal grafting in vitiligo. J Eur Acad Dermatol Venereol 2002;16:604-6.
73. Skouge J, Morison W, Diwan R, Rotter S. Autografting and PUVA. A combination therapy for vitiligo. J Dermatol Surg Oncol 1992;18:357-60.
74. Agrawal K, Agrawal A. Vitiligo: repigmentation with dermabrasion and thin split-thickness skin graft. Dermatol Surg 1995;21:295-300.
75. Kahn A, Cohen M. Vitiligo: treatment by dermabrasion and epithelial sheet grafting. J Am Acad Dermatol 1995,33:646-8.
76. Koga M. Epidermal grafting using the tops of suction blisters in the treatment of vitiligo. Arch Dermatol 1988;124:1656-8.
77. Falabella R. Surgical therapies for vitiligo. Clin Dermatol 1997;15:927-39.
78. Oh CK, Cha JH, Lim JY, Jo JH, Kim SJ, Jang HS, et al. Treatment of vitiligo with suction epidermal grafting by the use of an ultrapulse CO2 laser with a computerized pattern generator. Dermatol Surg 2001;27:565-8.
79. Kim HU, Yun SK. Suction device for epidermal grafting in vitiligo: employing a syringe and a manometer to provide an adequate negative pressure. Dermatol Surg 2000;26:702-4.
80. Njoo MD, Westerhof W, Bos JD, Bossuyrt PM. A systematic review of autologous transplantation methods in vitiligo. Arch Dermatol 1998;134:1543-9.
81. Brysk M, Newton R, Rajaraman S, Plott T, Barlow E, Bell T, et al. Repigmentation of vitiliginous skin by cultured cells. Pigment Cell Res 1989;2:202-7.
82. Lerner AB, Halaban R, Klaus SN, Moellmann GE. Transplantation of human melanocytes. J Invest Dermatol 1987;89:219-24.
83. Olsson MJ, Juhlin L. Transplantation of melanocytes in vitiligo. Br J Dermatol 1995;132:587-91.
84. Halder RM, Pham HN, Breadon JY, Johnson BA. Micropigmentation for the treatment of vitiligo. J Dermatol Surg Oncol 1989;15:1092-8.
85. Njoo MD, Westerhof W, Bos JD, Bossuyrt PM. The development of guidelines for the treatment of vitiligo. Clinical Epidemiology Unit of the Istituto Dermopatico dell'Immacolata-Istituto di Recovero e Cura a Carattere Scientifico (IDI-IRCCS) and the Archives of Dermatology. Arch Dermatol 1999;135:1514-21.